Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209014 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00209014 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 2 participants.
The verdict
NCT00209014, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00209014
The ClinicalTrials.gov registry entry for NCT00209014 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00209014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00209014 about?
NCT00209014 is a clinical study titled "Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease". Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.
What is the current status of trial NCT00209014?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2003-07. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00209014?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00209014?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.